Inovio's COVID-19 vaccine is protective against variants of concern

By The Science Advisory Board staff writers

Inovio has announced promising results from a study focusing on the human immune responses induced by its DNA vaccine candidate for COVID-19, INO-4800.

Results showed that INO-4800 induced a robust T-cell response against all spike protein variants tested, which may be a key in providing protection against SARS-CoV-2 variants. In addition, the vaccine provides similar levels of neutralizing activity against both the U.K. and Brazilian variants of SARS-CoV-2 as those against the original strain.

More than 3,000 patients are receiving Inovio's investigational DNA medicines in more than 7,000 applications across a range of clinical trials. This latest study has been submitted for peer review and can be viewed on bioRxiv.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking